Skip to main content

Table 2 Biomarker levels. Median [IQR] biomarker concentrations in patients according to positive or negative primary endpoint (KDIGO stage 2 or 3 AKI at 24 h)

From: Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort

 AKI stage 2 or 3 at 24 h (n = 49)AKI stage 0 or 1 at 24 h (n = 611)p value
uCHI3L1 (ng/mL)3.92 [0.12–12.45]0.44 [0.12–2.42]< 0.001
TIMP-2 (ng/mL)6.40 [3.15–10.15]3.40 [1.80–6.10]< 0.001
IGFBP7 (ng/mL)109.0 [46.9–300.9]64.3 [32.4–128.9]0.01
NephroCheck Risk® (ng/mL)2/10000.96 [0.19–2.64]0.22 [0.06–0.85]< 0.001
NephroCheck Risk® > 0.3 and ≤ 2.0 (ng/mL)2/100022/49 (44.9%)190/611 (31.1%)< 0.001
NephroCheck Risk® > 2.0 (ng/mL)2/100014/49 (28.6%)75/611 (12.3%)
uCHI3L1•TIMP-2 (ng/mL)219.18 [1.34–113.50]1.24 [0.27–13.95]< 0.001
uCHI3L1•IGFB7 (ng/mL)2199.6 [19.4–2932.9]20.9 [5.1–221.7]< 0.001
uCHI3L1•NephroCheck Risk® (ng/mL)3/10002.04 [0.11–28.13]0.09 [0.01–1.31]< 0.001